Giovanni Marconi

Ravenna, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 72 publications

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 27, 2026

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 02, 2026

Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 11, 2026

Disease course of FLT3 mutated extramedullary acute myeloid leukemia and efficacy of gilteritinib.

Disease course of FLT3 mutated extramedullary acute myeloid leukemia and efficacy of gilteritinib.

Journal: Haematologica

Published: January 14, 2026

Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Journal: Blood cancer journal

Published: December 04, 2025

Dynamics of IDH1/2 mutated clones in acute myeloid leukemia challenge their use as universal MRD markers.

Dynamics of IDH1/2 mutated clones in acute myeloid leukemia challenge their use as universal MRD markers.

Journal: Blood cancer journal

Published: November 30, 2025

NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort.

NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort.

Journal: Hematological oncology

Published: November 10, 2025

The role of menin inhibitors in acute myeloid leukemia.

The role of menin inhibitors in acute myeloid leukemia.

Journal: Current opinion in oncology

Published: August 21, 2025

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences risk of acute myeloid leukemia.

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences risk of acute myeloid leukemia.

Journal: Blood

Published: August 19, 2025

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.

Journal: Blood

Published: August 19, 2025

Unveiling Cryptic BCR-ABL1 Rearrangements: Diagnostic Challenges and Clinical Impact in Myeloid Malignancies.

Unveiling Cryptic BCR-ABL1 Rearrangements: Diagnostic Challenges and Clinical Impact in Myeloid Malignancies.

Journal: International journal of molecular sciences

Published: July 31, 2025

Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study.

Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study.

Journal: British journal of haematology

Published: July 29, 2025

Showing 1-12 of 72

Last Updated: 09/26/2026